... In 1959, McCoy and his ... requirements for in vitro cultivation ... studies were performed using,Basal Medium ... create a new medium known ...
Eagle's Ham's amino acids; EHAA...
... The active ingredient in Molecular Probes. ... appears to act as a free ... emission. Our original SlowFade formulation (S-2828) ... rate of fluorescein to almost zero ...
... more than doubles the benefits of high ... analysis cycles of the standard binary system ... tandem mode. Difficult separations are dramatically improved ... heartcut configurations, on-line sample preparation is fully ...
Biology Products:(Date:12/16/2009)... at Hahnemann among the Best in the Nation ... University Hospital proudly announces it has been granted ... (ANCC) Magnet Recognition Program(R). Magnet(R) is one of ... medical center can achieve, and places Hahnemann among ... that have achieved this prestigious distinction. ,, At ...
(Date:12/16/2009)... WALTHAM, Mass., Dec. 16 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that, ... Biotech/Janssen-Cilag,s Stelara and Abbott,s briakinumab (both interleukin inhibitors) ... in 2012 in the drug market for moderate ... will experience greater uptake, capturing nearly three times ...
(Date:12/16/2009)... InVitria has what scientists have been asking for! Zap-CHO is ... growth and productivity of CHO cells. Developed for scientists seeking ... well defined and consistent recombinant CHO supplement. , ... ... -- Scientists working with CHO cells can now access an ...
(Date:12/15/2009)... Epeius Biotechnologies Corporation, an emerging leader ... international validation of the cutting-edge science behind its ... around the world rediscovered the Cyclin G1 ... cancer pathogenesis and disease progression, and thus a ... the NIH National Cancer Institute investigating the role ...
Breaking Biology Technology:Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance 2Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3Biology NavigationMedical Navigation